NCT01069445

Brief Summary

Ageing of the population is a major event in the world. Gerontological/geriatric literature unanimously indicate that physical exercise and diet are at present the two available fundamental approaches to contrast/prevent most of the age associated alterations. In the elderly the inflammageing, the oxidative stress and the alteration of the intestinal microbiota can be influenced by nutritional status and possibly corrected by an appropriate dietetic intervention: Nowadays the nutraceutical food supplements become an opportunity for the consumer to improve the quality of individual diet for specific needs This study will focus on the development of a specific dietary approach through an E-Health dietary service, associated or not to nutraceutical food supplements intake, to modulate the oxidative stress, inflammageing and gut microflora in the elderly people.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2010

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 15, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 17, 2010

Completed
12 days until next milestone

Study Start

First participant enrolled

March 1, 2010

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2011

Completed
Last Updated

June 1, 2011

Status Verified

May 1, 2011

Enrollment Period

1.1 years

First QC Date

February 15, 2010

Last Update Submit

May 31, 2011

Conditions

Keywords

dietprobioticsinflammagingoxidative stressgut microbiotafood complements

Outcome Measures

Primary Outcomes (1)

  • The primary beneficial effect parameter is hsPCR (high-sensitivity C-reactive protein)

    2 months

Secondary Outcomes (6)

  • Inflammageing status: WBC, hemoglobin, ERS, fibrinogen, total cholesterol, triglycerides, insulin, glucose, (and HOMA Index), interleukin-6, TNFα, IL-10, TGF1, IGF-1, adiponectin, lectin, Homocysteine, folic acid and vitamin B12, calprotectin

    2 months

  • Oxidative stress: plasma total antioxidant capacity by TEAA (Trolox Equivalent Antioxidant Activity), glutathione level, the superoxide dismutase, the glutathione peroxidase, the glutathione reductase and the catalase activities

    2 months

  • Gut microbiota: expression of 16S ribosomal RNA in bacterial groups from faeces. Ratio between lactobacilli and clostridia bacteria. Real time PCR and PCR DGGE

    2 months

  • Quality of life: SF-36, GHQ, and daily VAS, ECOG performance status, IADL, Speilbeger Anxiety Scale, CES-D scale

    2 months

  • Physical performance status (SPPB), muscle function (hand-grip dynamometry), and physical activity level (IPAQ)

    2 months

  • +1 more secondary outcomes

Study Arms (4)

Diet advices

ACTIVE COMPARATOR

will receive the Optimal Diet for Elderly

Behavioral: Optimal Diet

Diet advices + VSL-3

EXPERIMENTAL

will receive the Optimal Diet for Elderly + VSL#3® probiotic blend

Dietary Supplement: VSL#3® probiotic blend

Diet advices + 5203-L

EXPERIMENTAL

will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene

Dietary Supplement: AISA-5203-L fruit extracted terpene

Diet advices + Argan oil

EXPERIMENTAL

will receive the Optimal Diet for Elderly + Argan oil

Dietary Supplement: Argan oil

Interventions

VSL#3® probiotic blendDIETARY_SUPPLEMENT

Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water

Diet advices + VSL-3

Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water

Diet advices + 5203-L
Argan oilDIETARY_SUPPLEMENT

Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water

Diet advices + Argan oil
Optimal DietBEHAVIORAL

a dietician will train each subject (or the caregiver) to use the personalized diet on web platform.

Diet advices

Eligibility Criteria

Age65 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)

You may qualify if:

  • Age: from 65 to 85 years
  • Body Mass Index: 22-30 kg/m2
  • ECOG Performance status: WHO performance score 0 to 2
  • Absence of known diseases and/or abnormalities of haematological parameters (haematological, inflammatory, metabolic, hepatic and renal diseases)
  • The subjects must be able to comply with management of nutraceutical products and with scheduled follow-up
  • The subjects must be able to use the computer and to access to the web, by themselves or with the help of a caregiver

You may not qualify if:

  • History of significant neurologic or psychiatric disorders including dementia, seizures, bipolar disorder
  • Geriatric anorexia \[less than 2 full meals per day and /or less than one serving of dairy products (milk, cheese, yogurt) per day or two or more servings of legumes or eggs per week or one serving of meat, fish or poultry every day\]
  • Weight loss \> 5% in the last month
  • Previous antibiotic treatment within 4 months
  • Active infection requiring per OS or IV antibiotics, including active tuberculosis, known and declared HIV, HCV
  • Constipation and/or abdominal pain/discomfort that require dietary supplements or medical therapy
  • Gastric disease that requires medical therapy (e.g. gastric secretion inhibitory drugs)
  • Chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis, diverticulosis, diverticulitis)
  • Diabetes mellitus
  • Dislipidemia and/or any metabolic disease that requires medical or dietetic treatment
  • Myocardial infarction within 6 months prior to study entry, congestive heart disease, uncontrolled cardiac insufficiency, and any current grade 3 or 4 cardio-vascular disorder despite treatment
  • Current history of neoplasm except for curatively treated non melanoma skin cancer or in situ carcinoma of the cervix and except for other cancer curatively treated and with no evidence of disease for at least 5 years
  • Other sever underlying medical conditions, which could impair the ability of the patient to participate in the study
  • Previous (within 15 days) or concomitant treatment that modifies intestinal absorption (e.g. metformine, acarbose in diabetic treatment…)
  • Probiotics, prebiotics or simbiotics (yogurt or another functional foods) intake in the last 3 weeks
  • +6 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pôle de gerontology Clinique Hôpital Xavier Arnozan , University Hospital, Bordeaux

Pessac, 33600, France

Location

Related Publications (6)

  • Franceschi C, Valensin S, Bonafe M, Paolisso G, Yashin AI, Monti D, De Benedictis G. The network and the remodeling theories of aging: historical background and new perspectives. Exp Gerontol. 2000 Sep;35(6-7):879-96. doi: 10.1016/s0531-5565(00)00172-8.

    PMID: 11053678BACKGROUND
  • Wener MH, Daum PR, McQuillan GM. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol. 2000 Oct;27(10):2351-9.

    PMID: 11036829BACKGROUND
  • Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996 Apr 27;312(7038):1061-5. doi: 10.1136/bmj.312.7038.1061.

    PMID: 8616412BACKGROUND
  • Devaraj S, O'Keefe G, Jialal I. Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab. 2005 Aug;90(8):4549-54. doi: 10.1210/jc.2005-0069. Epub 2005 May 17.

    PMID: 15899961BACKGROUND
  • Ostan R, Bene MC, Spazzafumo L, Pinto A, Donini LM, Pryen F, Charrouf Z, Valentini L, Lochs H, Bourdel-Marchasson I, Blanc-Bisson C, Buccolini F, Brigidi P, Franceschi C, d'Alessio PA. Impact of diet and nutraceutical supplementation on inflammation in elderly people. Results from the RISTOMED study, an open-label randomized control trial. Clin Nutr. 2016 Aug;35(4):812-8. doi: 10.1016/j.clnu.2015.06.010. Epub 2015 Jul 15.

  • Valentini L, Pinto A, Bourdel-Marchasson I, Ostan R, Brigidi P, Turroni S, Hrelia S, Hrelia P, Bereswill S, Fischer A, Leoncini E, Malaguti M, Blanc-Bisson C, Durrieu J, Spazzafumo L, Buccolini F, Pryen F, Donini LM, Franceschi C, Lochs H. Impact of personalized diet and probiotic supplementation on inflammation, nutritional parameters and intestinal microbiota - The "RISTOMED project": Randomized controlled trial in healthy older people. Clin Nutr. 2015 Aug;34(4):593-602. doi: 10.1016/j.clnu.2014.09.023. Epub 2014 Oct 8.

MeSH Terms

Interventions

argan oil

Study Officials

  • Isabelle BOURDEL-MARCHASSON, Professor

    University Hospital, Bordeaux

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

February 15, 2010

First Posted

February 17, 2010

Study Start

March 1, 2010

Primary Completion

April 1, 2011

Study Completion

April 1, 2011

Last Updated

June 1, 2011

Record last verified: 2011-05

Locations